Murray Stahl's AZN Position Overview
Murray Stahl (via Horizon Kinetics Asset Management LLC) currently holds 11,476 shares of AstraZeneca PLC (AZN) worth $880,439, representing 0.01% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Murray Stahl has maintained a long-term strategic position in AZN, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2015, adding 26,000 shares. Largest reduction occurred in Q3 2015, reducing 24,000 shares.
Analysis based on 13F filings available since 2013 Q2
Murray Stahl's AstraZeneca PLC (AZN) Holding Value Over Time
Track share changes against reported price movement
Quarterly AstraZeneca PLC (AZN) Trades by Murray Stahl
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +24,002 | Add 0.00% | 24,000 | $23.67 |
| Q3 2013 | +40 | Add 0.17% | 24,040 | $25.96 |
| Q1 2014 | +2,172 | Add 9.03% | 26,212 | $32.43 |
| Q2 2014 | -212 | Reduce 0.81% | 26,000 | $37.15 |
| Q2 2015 | +26,000 | Add 100.00% | 52,000 | $15.92 |
| Q3 2015 | -24,000 | Reduce 46.15% | 28,000 | $31.82 |
| Q1 2016 | +302 | Add 1.08% | 28,302 | $28.16 |
| Q2 2017 | +235 | Add 0.83% | 28,537 | $34.10 |
| Q3 2017 | +2,708 | Add 9.49% | 31,245 | $33.86 |
| Q4 2017 | -162 | Reduce 0.52% | 31,083 | $34.68 |
| Q1 2018 | -600 | Reduce 1.93% | 30,483 | $34.97 |
| Q2 2018 | -3,220 | Reduce 10.56% | 27,263 | $35.10 |
| Q3 2018 | -2,000 | Reduce 7.34% | 25,263 | $39.58 |
| Q1 2019 | +25,264 | Add 0.00% | 25,263 | $40.41 |
| Q1 2020 | -4,000 | Reduce 15.83% | 21,263 | $44.68 |
| Q4 2020 | -2,000 | Reduce 9.41% | 19,263 | $49.99 |
| Q2 2021 | -4,000 | Reduce 20.77% | 15,263 | $59.88 |
| Q2 2022 | -205 | Reduce 1.34% | 15,058 | $66.08 |
| Q3 2022 | +34 | Add 0.23% | 15,092 | $54.86 |
| Q4 2022 | -1,034 | Reduce 6.85% | 14,058 | $67.80 |
| Q3 2023 | -80 | Reduce 0.57% | 13,978 | $67.72 |
| Q4 2023 | -574 | Reduce 4.11% | 13,404 | $67.35 |
| Q1 2024 | +2 | Add 0.01% | 13,406 | $67.75 |
| Q2 2024 | -436 | Reduce 3.25% | 12,970 | $77.99 |
| Q3 2024 | -616 | Reduce 4.75% | 12,354 | $77.91 |
| Q4 2024 | +522 | Add 4.23% | 12,876 | $65.52 |
| Q1 2025 | -20 | Reduce 0.16% | 12,856 | $73.50 |
| Q2 2025 | -904 | Reduce 7.03% | 11,952 | $69.88 |
| Q3 2025 | -476 | Reduce 3.98% | 11,476 | $76.72 |
Murray Stahl's AstraZeneca PLC Investment FAQs
Murray Stahl first purchased AstraZeneca PLC (AZN) in Q2 2013, acquiring 24,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Murray Stahl has held AstraZeneca PLC (AZN) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Murray Stahl's largest addition to AstraZeneca PLC (AZN) was in Q2 2015, adding 52,000 shares worth $828,000. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Murray Stahl's firm, Horizon Kinetics Asset Management LLC, owns 11,476 shares of AstraZeneca PLC (AZN), valued at approximately $880,439. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, AstraZeneca PLC (AZN) represents approximately 0.01% of Murray Stahl's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Murray Stahl's peak holding in AstraZeneca PLC (AZN) was 52,000 shares, as reported at the end of Q2 2015. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.